Recent News for OVID - Ovid Therapeutics Inc.

Date Title
Jan 18 Ovid Therapeutics: Residual Value In OV935 After The OV101 Fiasco
Jan 15 Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
Jan 14 Revisiting Ovid Therapeutics
Dec 16 Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
Dec 16 Is OVID A Good Stock To Buy Right Now?
Dec 2 Mid-Afternoon Market Update: Dow Edges Higher; Sequential Brands Shares Spike Higher
Dec 2 Why Ovid Therapeutics Stock Is Imploding Today
Dec 2 Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Ovid Therapeutics Inc. (OVID) Investigation
Dec 2 Benzinga's Top Upgrades, Downgrades For December 2, 2020
Dec 2 The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
Dec 1 Ovid Therapeutics misses goal in Angelman syndrome treatment
Dec 1 Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
Nov 29 The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Nov 25 Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?
Nov 23 Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
Nov 16 These Analysts Think Ovid Therapeutics Inc.'s (NASDAQ:OVID) Sales Are Under Threat
Nov 12 Ovid Therapeutics EPS beats by $0.14, beats on revenue
Nov 12 Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Oct 5 Opthea to Appoint Dr Jeremy Levin as Chairman of the Board
Sep 30 Ovid's soticlestat shows positive effect in rare epilepsies
Sep 26 The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Sep 11 Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Aug 28 Ovid Therapeutics: Strong Buy After Fall On Necessary Dilution Backed By Positive Data
Aug 25 The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout
Aug 25 Ovid prices $50M stock offering at $8 per share
Back to the Main OVID Page...